Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Tables)

v3.10.0.1
Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2018
Notes Tables  
Schedule of Franchisor Disclosure [Table Text Block]
    Three Months Ended   Nine Months Ended
    September 30,   September 30,
Franchised clinics:   2018   2017   2018   2017
Clinics open at beginning of period    
365
      
336
      
352
      
309
  
Opened or purchased during the period    
10
      
6
      
25
      
35
  
Acquired during the period    
-
      
-
      
(1
 )    
-
  
Closed during the period    
(1
 )    
-
      
(2
 )    
(2
 )
Clinics in operation at the end of the period    
374
      
342
      
374
      
342
  
    Three Months Ended   Nine Months Ended
    September 30,   September 30,
Company-owned or managed clinics:   2018   2017   2018   2017
Clinics open at beginning of period    
48
      
47
      
47
      
61
  
Opened during the period    
-
      
-
      
-
      
-
  
Acquired during the period    
-
      
 
      
1
      
-
  
Closed or sold during the period    
-
      
-
      
-
      
(14
 )
Clinics in operation at the end of the period    
48
      
47
      
48
      
47
  
                                 
Total clinics in operation at the end of the period    
422
      
389
      
422
      
389
  
                                 
Clinic licenses sold but not yet developed    
126
      
105
      
126
      
105
  
Executed letters of intent for future clinic licenses    
12
      
5
      
12
      
5
  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
    Three Months Ended   Nine Months Ended
    September 30,   September 30,
    2018   2017   2018   2017
        (as adjusted)       (as adjusted)
Net loss   $
(151,803
 )   $
(431,705
 )   $
(581,486
 )   $
(3,219,232
 )
                                 
Weighted average common shares outstanding - basic    
13,727,712
      
13,262,032
      
13,646,599
      
13,144,764
  
Effect of dilutive securities:                                
Unvested restricted stock, stock options and warrants    
-
      
-
      
-
      
-
  
Weighted average common shares outstanding - diluted    
13,727,712
      
13,262,032
      
13,646,599
      
13,144,764
  
                                 
Basic and diluted loss per share   $
(0.01
 )   $
(0.03
 )   $
(0.04
 )   $
(0.24
 )
Anti-Dilutive shares:                
    Three Months Ended   Nine Months Ended
    September 30,   September 30,
    2018   2017   2018   2017
     Unvested restricted stock    
51,134
      
63,700
      
51,134
      
63,700
  
     Stock options    
960,213
      
1,011,686
      
960,213
      
1,011,686
  
     Warrants    
90,000
      
90,000
      
90,000
      
90,000
  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]
    As of December
31, 2017		   Adjustments Due
to ASC 606
Adoption		   As of December
31, 2017
ASSETS  
(as reported)
  
 
  
(as adjusted)
Current assets:                        
Deferred franchise costs - current portion   $
484
 
   $
14
     $
498
 
Total current assets    
6,657
 
    
14
      
6,671
 
Deferred franchise costs, net of current portion    
813
 
    
1,500
      
2,313
 
Deposits and other assets    
612
 
    
12
      
623
 
Total assets   $
16,910
 
   $
1,526
     $
18,436
 
                         
LIABILITIES AND STOCKHOLDERS' EQUITY                        
Current liabilities:                        
Deferred franchise revenue - current portion   $
1,686
 
   $
308
     $
1,994
 
Other current liabilities    
49
 
    
104
      
153
 
Total current liabilities    
4,967
 
    
412
      
5,379
 
Deferred revenue, net of current portion    
4,693
 
    
4,859
      
9,553
 
Total liabilities    
12,011
 
    
5,271
      
17,283
 
Stockholders' equity:                        
Accumulated deficit    
(32,259
)
    
(3,745
 )    
(36,004
)
Total stockholders' equity    
4,899
 
    
(3,745
 )    
1,153
 
Total liabilities and stockholders' equity   $
16,910
 
   $
1,526
     $
18,436
 
    Three Months Ended
September 30, 2017		   Three Months Ended
Adjustments Due
to ASC 606
Adoption		   Three Months Ended
September 30, 2017
    (as reported)       (as adjusted)
Revenues:            
Franchise fees   $
230
     $
152
     $
382
  
Regional developer fees    
259
      
(160
 )    
99
  
Total revenues    
6,546
      
(8
 )    
6,538
  
Cost of revenues:                        
Franchise cost of revenues    
716
      
20
      
736
  
Total cost of revenues    
819
      
20
      
839
  
Loss from operations    
(378
 )    
(28
 )    
(406
 )
Loss before income tax expense    
(368
 )    
(28
 )    
(396
 )
Net loss and comprehensive loss   $
(404
 )   $
(28
 )   $
(432
 )
                         
Loss per share:                        
Basic and diluted loss per share   $
(0.03
 )   $
(0.00
 )   $
(0.03
 )
    Nine Months Ended
September 30, 2017		   Nine Months Ended
Adjustments Due
to ASC 606
adoption		   Nine Months Ended
September 30, 2017
    (as reported)       (as adjusted)
Revenues:                        
Franchise fees   $
1,037
     $
4
     $
1,041
  
Regional developer fees    
456
      
(194
 )    
262
  
Total revenues    
18,235
      
(189
 )    
18,045
  
Cost of revenues:                        
Franchise cost of revenues    
2,104
      
(32
 )    
2,071
  
Total cost of revenues    
2,332
      
(32
 )    
2,299
  
Loss from operations    
(2,949
 )    
(157
 )    
(3,106
 )
Loss before income tax expense    
(2,983
 )    
(157
 )    
(3,140
 )
Net loss and comprehensive loss   $
(3,062
 )   $
(157
 )   $
(3,219
 )
                         
Loss per share:                        
Basic and diluted loss per share   $
(0.23
 )   $
(0.01
 )   $
(0.24
 )